A Phase 4 interventional study of TRPTI and Placebo in Overweight , Obesity, sponsored by RDC Clinical Pty Ltd. Not yet recruiting at 1 site in Australia. Open to participants aged 30 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-30.
Sponsored by RDC Clinical Pty Ltd · Phase 4, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 188 studies in Obesity with a site in Australia — 56 open to participants now, 74 under way, 34 of them phase 3. Obesity · Australia.
Among the 188 studies in Obesity with a site in Australia, this one is the 158th largest by planned enrollment of the 169 interventional ones that give a count, is one of 41 that started in 2026, is one of 8 in phase 4, reaches primary completion later than 30 of the 73 other live ones, and was the 179th registered.
11,556 studies on the registry are indexed under Obesity; 2,055 are open to participants now.
Browse Obesity studies →56 of the 188 studies in Obesity with a site in Australia are open now. Recruiting first, the newest first:
Pfizer · Sites in Australia, United States
Ages 18+
AstraZeneca · Sites in Australia, United States, Argentina and 13 more countries
Ages 18+
AstraZeneca · Sites in Australia, United States, Argentina and 13 more countries
Ages 18+
Amgen · Sites in Australia, United States, Canada and 2 more countries
Ages 18–99
Verdiva Bio Dev Limited · Sites in Australia
Ages 18–60 · Healthy volunteers
A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →
Of the 1,346 Obesity studies recruiting now, 379 (28%) set no upper age limit and 863 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.
This study: 30 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
188 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 38 · Phase 2 34 · Phase 3 59 · Phase 4 8
First in 1995; this study’s year is marked. 41 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 20 is below the median of 67 across 9,036 interventional studies indexed under Obesity.
Median enrollment 180 across the 169 interventional studies, 626 across the 19 observational. Of the 97 that completed or were terminated, 14 (14%) have results posted.
This tab as a report to print or save as PDF → With an account.
130 of 188 have an industry lead sponsor. The 10 most frequent:
RDC Clinical Pty Ltd is the lead sponsor of 34 studies on the registry; 8 are open to participants now.
RDC Clinical Pty Ltd has 1 study filed under Obesity — fewer than ten, so there is no comparison to draw.
25 of the studies in Obesity with a site in Australia that are under way reach primary completion within a year, 6 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06858839Phase 3AmgenEvaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight | 2027-01-21 |
| NCT07220642Phase 3Novo Nordisk A/SWeight Loss in People Living With Overweight or Obesity Following Treatment With Cagrilintide | 2027-05-11 |
| NCT07225686Phase 3AmgenMaridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy | 2027-08-20 |
| NCT07226765Phase 3AmgenMaridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea Not on Positive Airway Pressure (PAP) Therapy | 2027-08-30 |
| NCT05556512Phase 3Eli Lilly and CompanyA Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity | 2027-10 |
Add all 25 to your calendar (.ics) → With an account.
Among the 188 studies in Obesity with a site in Australia, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to assess whether TRPTI™ supplementation affects GLP-1 and related metabolic markers in generally healthy adults who are overweight or obese (BMI 25.0-34.9 kg/m², aged 30 years and older).
Researchers will compare TRPTI™ 150 mg to a matching placebo capsule to see if TRPTI™ produces a meaningful difference in GLP-1 response and associated metabolic and appetite-related markers over 8 hours.
Participants will attend two 9-hour clinic visits (crossover design, with a minimum 6-day washout between visits).
11,556 studies on the registry are indexed under Obesity; 2,055 are open to participants now.
This study's planned enrollment of 20 is below the median of 67 across 9,036 interventional studies indexed under Obesity.
Browse Obesity studies →RDC Clinical Pty Ltd is the lead sponsor of 34 studies on the registry; 8 are open to participants now.
Compared within Obesity, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Overweight. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive a single capsule of 150mg TRPTI
Dietary Supplement: TRPTI
Participants will receive a single capsule of placebo
Other: Placebo
Participants will receive a single capsule of 150mg TRPTI
Also known as: Oleoylethanolamide
Participants will receive a single capsule of placebo
Change from baseline in plasma GLP-1 concentration
Change from baseline in plasma GLP-1 concentration at each individual post-dose time point (0.25, 0.5, 0.75, 1.0, 1.5, 2.0, 2.5, 3, 4, 5, 6, 7, and 8-hours post-dose). Comparing TRPTI 150 mg to placebo
Time frame: Baseline to 8hrs
GLP-1 area under the curve (AUC)
GLP-1 area under the curve (AUC) 0: total (0-8 h) and pre-defined blocks (0-15 min, 15 min-2 h, 2-4 h, 4-6 h, 6-8 h). Comparing TRPTI 150 mg to placebo
Time frame: Baseline to 8hrs
Change from baseline at each individual time point for: GIP
Change from baseline at each individual time point for: GIP
Time frame: Baseline to 8hrs
Change from baseline at each individual time point for: DPP-4 (dipeptidyl peptidase-4)
Change from baseline at each individual time point for: DPP-4 (dipeptidyl peptidase-4)
Time frame: Baseline to 8hrs
Change from baseline at each individual time point for: glucose
Change from baseline at each individual time point for: glucose
Time frame: Baseline to 8hrs
Change from baseline at each individual time point for: insulin
Change from baseline at each individual time point for: insulin
Time frame: Baseline to 8hrs
AUC (total and blocks) for: GIP
AUC (total and blocks) for: GIP
Time frame: Baseline to 8hrs
AUC (total and blocks) for: DPP-4
AUC (total and blocks) for: DPP-4
Time frame: Baseline to 8hrs
AUC (total and blocks) for: glucose
AUC (total and blocks) for: glucose
Time frame: Baseline to 8hrs
AUC (total and blocks) for: insulin
AUC (total and blocks) for: insulin
Time frame: Baseline to 8hrs
Tmax for GLP-1
Tmax for GLP-1
Time frame: Baseline to 8hrs
Tmax for DPP-4
Tmax for DPP-4
Time frame: Baseline to 8hrs
Tmax for glucose
Tmax for glucose
Time frame: Baseline to 8hrs
Tmax for insulin
Tmax for insulin
Time frame: Baseline to 8hrs
Cmax for GLP-1
Cmax for GLP-1
Time frame: Baseline to 8hrs
Cmax for DPP-4
Cmax for DPP-4
Time frame: Baseline to 8hrs
Cmax for glucose
Cmax for glucose
Time frame: Baseline to 8hrs
Cmax for insulin
Cmax for insulin
Time frame: Baseline to 8hrs
Tolerability including GIT tolerance
Tolerability including gastrointestinal (GIT) tolerance will be measured via a Gastronintestinal tolerance questionnaire and GIT adverse events.
Time frame: Baseline to 8 hours
Safety via AE monitoring
Safety via AE monitoring
Time frame: Baseline to 8 hours
Exploratory: Change from baseline at each individual time point for glucagon
Exploratory: Change from baseline at each individual time point for glucagon
Time frame: Baseline to 8 hours
Exploratory: Change from baseline at each individual time point for PYY (peptide YY)
Exploratory: Change from baseline at each individual time point for PYY (peptide YY)
Time frame: Baseline to 8 hours
Exploratory: AUC (total and blocks) for glucagon
AUC (total and blocks) for glucagon
Time frame: Baseline to 8 hours
Exploratory: AUC (total and blocks) for PYY
AUC (total and blocks) for PYY
Time frame: Baseline to 8 hours
Exploratory: Tmax for glucagon
Tmax for glucagon
Time frame: Baseline to 8 hours
Exploratory: Tmax for PYY
Tmax for PYY
Time frame: Baseline to 8 hours
Exploratory: Cmax for glucagon
Tmax for glucagon
Time frame: Baseline to 8 hours
Exploratory: Cmax for PYY
Tmax for PYY
Time frame: Baseline to 8 hours
Exploratory: Visual analogue scale (VAS) for appetite
VAS for appetite
Time frame: Baseline to 8hrs
Exploratory: Food consumption during time in clinic
Food consumption during time in clinic
Time frame: Baseline to 8 hours
Exploratory: E/LFT
Blood sample taken for E/LFT
Time frame: Baseline to 8 hours
Exploratory: Subgroup analysis by BMI stratum
Subgroup analysis by BMI stratum (BMI 25.0-29.9 vs BMI 30.0-34.9).
Time frame: Baseline
Plan to share: Undecided
No publications or documents are linked to this record.
Start is estimated for Oct 2026; primary completion for Oct 2027, 12 months later.
Of 210 phase 4 interventional studies under Obesity, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 51. This study's planned 12 months is below that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: N-oleoylethanolamine